Correspondence  by unknown
cutoffs.” (p. 446). In calculating sensitivity, we need to classify as
true positive results those with an NI score within or greater than
the category established as the cutoff score for a positive test result.
For example, all 68 of the patients with disease have at least a score
of category 3 (NI 4 to ,6). Thus, the sensitivity for category 3 is
100%. In calculating specificity, we need to classify as true negative
results those with an NI score lower than the category established
as the cutoff score for a positive test result. For example, all 223 of
the patients without disease have an NI score of category 1 or
greater. Because an NI score of 0 is within category 1, it is logical
that the specificity for category 1 would be 0%. There are no true
negative results for category 1. I have corrected the sensitivities and
specificities in Table 4 as required.
Because the authors’ sensitivities were often incorrect, their
positive likelihood ratios and negative likelihood ratios are also
flawed. In addition, the authors erred in the formula used for the
negative likelihood ratio. On page 446, the authors give the
formulas for the positive likelihood ratio and the negative likeli-
hood ratio. This latter formula is incorrect. The negative likelihood
ratio is a false negative rate divided by a true negative rate, or 1 2
sensitivity/specificity. The authors’ mistake was to invert the
numerator and denominator.
Using inaccurate sensitivities and specificities and a flawed
formula for the negative likelihood ratio, the authors’ Table 4
reports incorrect calculations for their post-test probabilities. In my
redone Table 4, I also report the correct post-test probabilities. I
hope these correctly calculated sensitivities and specificities, like-
lihood ratios and post-test probabilities will be helpful to your
readers as they assess the value of this otherwise well-conducted
study for their clinical practice.
Ronald J. Markert, PHD
Professor of Internal Medicine
Wright State University School of Medicine
Dayton, Ohio
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We thank Dr. Markert for his interest in our work, but would like
to point out that there are no errors in the table or flawed data. The
noninvasive index categories defined in Table 4 of our article
comprise patients with and without angiographic three-vessel
and/or left main coronary artery disease, as explained in the table.
Regarding calculations of sensitivities and specificities, we did not
specify in the Methods section or Table 4 what was done with the
interval itself (the specific row category), and we apologize for any
confusion this may have caused. In fact, we always included the
row in question in the lower category, thus using the “upper” limit
of the category as the test threshold value. Dr. Markert would have
preferred our using the “lower” limit of the category, but this is
only a nonsubstantial difference in the presentation of the data.
The likelihood ratios, as presented in our study, are correct. In
particular, the formula for the negative likelihood ratio given in our
report, as well as the way in which it was used, is correct. This is
intuitively apparent when one considers that the formula suggested
by Dr. Markert, using the inverse of our ratio, yields a posttest
probability of disease and a posttest probability of no disease, both
increasing in the same direction. We used the formulas presented
in the Methods section of our article in a consistent fashion,
seeking to express the strength with which a positive or negative
test result reinforced a positive or negative conclusion, respectively.
The posttest probability of no disease was calculated on the basis
of a negative test result (value below cutoff). The author of
reference 27 cited in our study has seen and verified our version of
this formula.
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Enhanced Activity of Sodium–Lithium
Countertransport in Patients With Cardiac
Syndrome X: A Potential Link Between
Cardiac and Metabolic Syndrome X
We read with interest the article by Gaspardone et al. (1) detailing
their work with cardiac patients with syndrome X. These authors
have shown the clearest separation in sodium–lithium counter-
transport (SLC) activity between patients and healthy control
subjects since activity was first described by Canessa et al. (2) in
1980, who showed a clear difference between hypertensive patients
and normotensive volunteers. The possibility of using SLC activity
as a marker for predisposition to hypertension and for differenti-
ation between primary and secondary forms of the disease naturally
followed (3). However, subsequent studies were unable to repro-
duce the clear separation (4). It was eventually realized that the
overlap of activity values between healthy and hypertensive subjects
restricted the value of SLC as a prognostic test. In later years, it
emerged that the patients in the 1980 study represented some of
the most severely affected patients attending the hypertension
clinic in Boston at that time (Dr. Canessa, personal communica-
tion, Boston, Massachusetts, 1991). Nevertheless, study of SLC
raised interesting questions as to how a defect in a cell membrane
transporter could relate to the development of hypertension.
In the mid 1980s, focus shifted from SLC as a marker of
hypertension to the associations between behavior of this trans-
porter and metabolic disorders. It is now generally accepted that
expression of SLC is in some way linked to insulin resistance,
vascular disease and diabetes (5). However, until now, no clear
differentiation has been shown between SLC activity in health and
that in disease, and no specific pathophysiologic link between SLC
and vascular disease has been reported. In making this observation
in such a specific group of patients, Gaspardone et al. (1) bring us
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a step closer to discovering the connection between these condi-
tions. Unfortunately, several methodologic limitations have re-
stricted interpretation of the data from the present study. Gasp-
ardone et al. use the method first proposed by Canessa et al.,
without making allowances for changes to assay methodology over
the past two decades. First, the issue of using magnesium in the
sodium-free media has not been addressed. This may have had
subtle effects on outcomes of SLC characterization (5,6). Second,
Gaspardone et al. fail to recognize the issue of distribution of SLC
activity within populations (1). Activity of SLC is not normally
distributed and as such should not be reported as a mean value 6
SD (4,5). Finally, determining activity as opposed to performing
kinetic characterization prevents the work of Gaspardone et al.
from being put into context with recent investigations into SLC
behavior. Kinetic investigations have confirmed the critical roles of
the maximal rate of turnover (Vmax) and external affinity constant
(km) in the relation between SLC behavior and various disease
processes (4,5). These two constants appear to represent two
distinct SLC characteristics operating under different influences.
In hypertension, km is altered—expressed in the form of a lower
km, possibly reflecting a higher affinity for external sodium that
may have a genetic basis (4,5). With regard to the broader issue of
vascular disease, there is evidence to suggest low km in patients
with coronary artery disease (7). In the case of diabetes, reduced km
occurs when the patient has nephropathy; however, Vmax is also
reduced (4,5). In contrast, patients with chronic diabetes with no
evidence of renal damage demonstrate elevated Vmax. Further-
more, Vmax is related to fluidity of the erythrocyte membrane (4,5).
This suggests that environmental factors such as plasma lipids may
be exerting effects on the countertransporter. Changes in SLC
behavior associated with diabetes may therefore relate to patho-
logic changes in lipid metabolism and membrane fluidity.
Gaspardone et al. make two controversial assumptions in their
work. First, in claiming to have determined Vmax using the method
of Canessa et al., Gaspardone et al. is incorrect (1). The method of
Canessa et al. measures a lithium efflux rate under highly specific
conditions that are not representative of the biochemical constant
Vmax (4,5). Second, in their interpretation of their findings,
Gaspardone et al. relate the abnormal SLC activity in their
patients with syndrome X to the expression of abnormal behavior
in the sodium–hydrogen exchanger (SHE) (1). We recognize that
similarities between these membrane transporters support the
hypothesis that SHE and SLC represent different functional
responses of a single membrane protein. However, it is well
accepted that there are several missing links that stand in the way
of the confirmation of this otherwise attractive theory, and we
caution against too ready acceptance (5,8). Furthermore, the
cluster of “dowels” that Gaspardone et al. suggest may be linked by
enhanced SHE activity, including coronary prearteriolar dysfunc-
tion, hyperinsulinemia and the predominance of sympathetic
activity, could equally be explained by defects in the cell membrane
itself. The membrane resident receptors, enzymes and transporters
that mediate many of these processes are sensitive to the compo-
sition of the cell membrane, and major changes in the properties of
the membrane can be imposed by minor alterations in lipid
composition (9). Such alterations could also explain the abnormal
SLC behavior noted in the study of Gaspardone et al. (1). The
aforementioned hypothesis does not require a specific error in the
coding of a single transporter and relates these observations more
to environmental rather than genetic factors.
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REPLY
Considerations by Hardman et al. about the recent identification
of a clearcut elevation of the maximal velocity (Vmax) of red blood
cell sodium–lithium countertransport (SLC) in patients with
cardiac syndrome X (1) are of interest. These authors state that the
identification of increased SLC activity in essential hypertension
(2) has not been confirmed by some subsequent studies, and they
conclude that it is not possible to predict hypertension on the basis
of the Vmax of SLC. We fully agree with these conclusions.
However, it needs to be clarified that our study was carried out in
a very select group of patients with cardiac rather than metabolic
syndrome X (3) who are by definition normotensive. Thus,
Hardman et al. seem to mistake cardiac for metabolic syndrome X.
Consequently, it is difficult for us to comment on the role of a
condition (i.e., hypertension) that was absent in our patients and
was an exclusion criterium for patient selection.
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